Get the app
US › Healthcare

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

US · Healthcare · Biotechnology

$1.09+12.37%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-3.3M
EPS
$-1.14
EPS estimate
$-1.16

EPS came in at -1.14 against a street estimate of -1.16 — a beat of 1.7%.

Key statistics

Market cap
$3.5M
Forward P/E
0.0
P/B
1.15
Book value
$1.32
EPS (TTM)
$-5.02
52-week high
$14.21
52-week low
$0.82
50-day MA
$1.34
200-day MA
$4.34
Beta
1.95

Analyst view

Analysts rate Cadrenal Therapeutics, Inc. Common Stock a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $14.00.

Shareholding

Insiders
9.66%
Institutions
9.75%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.41%
HRT FINANCIAL LLC0.81%
Geode Capital Management, LLC0.53%
Vanguard Fiduciary Trust Co0.23%
Tower Research Capital LLC0.04%
UBS Group AG0.03%
Coconut Grove Bank0.03%
Hartland & Co0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cadrenal Therapeutics, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.